@jturb85: Daraxonrasib is poised to become the new standard of care for previously treated metastatic #pancreaticcancer after detailed results from a Phase III clinical trial were released at the American Society of Clinical Oncology (ASCO) annual meeting this weekend. 💊 The presentation expanded on data previously provided by the oncology company Revolution Medicines in a press release in April. The once-daily pill essentially doubles overall survival in patients with previously treated metastatic pancreatic cancer compared with standard intravenous chemotherapy. This weekend’s #ASCO26 meeting provided new insights into effectiveness, safety, side effects and more. View the top take-aways including what this means for patients, what's next and how PanCAN Patient Services can help at 🔗 http://pcan.at/rjul9sza #pancreacticcancer

Jessica Ann 💜

Open In TikTok:

Region: US

Tuesday 02 June 2026 20:18:21 GMT